HC Wainwright Forecasts Reduced Earnings for TG Therapeutics

TG Therapeutics, Inc. (NASDAQ:TGTX) – Analysts at HC Wainwright reduced their Q2 2026 earnings estimates for TG Therapeutics in a research note issued to investors on Monday, July 13th. HC Wainwright analyst E. Bodnar now expects that the biopharmaceutical company will earn $0.22 per share for the quarter, down from their prior estimate of $0.36. HC Wainwright currently has a “Buy” rating and a $77.00 target price on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $1.51 per share. HC Wainwright also issued estimates for TG Therapeutics’ Q3 2026 earnings at $0.28 EPS, FY2026 earnings at $0.99 EPS, FY2028 earnings at $3.81 EPS, FY2029 earnings at $4.70 EPS and FY2030 earnings at $5.84 EPS.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.23 by ($0.11). TG Therapeutics had a net margin of 65.95% and a return on equity of 88.73%. The company had revenue of $204.92 million during the quarter, compared to analyst estimates of $200.33 million. During the same quarter last year, the firm earned $0.03 EPS. The business’s revenue was up 69.5% on a year-over-year basis.

A number of other equities analysts have also weighed in on TGTX. Weiss Ratings upgraded shares of TG Therapeutics from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, May 1st. Bank of America raised their price objective on shares of TG Therapeutics from $17.00 to $20.00 and gave the company an “underperform” rating in a research report on Tuesday, July 7th. Zacks Research raised TG Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, June 1st. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $83.00 price objective on shares of TG Therapeutics in a report on Monday, June 22nd. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $53.33.

TG Therapeutics Trading Down 0.2%

NASDAQ:TGTX opened at $54.89 on Wednesday. TG Therapeutics has a 12-month low of $25.28 and a 12-month high of $59.30. The company has a current ratio of 5.81, a quick ratio of 5.12 and a debt-to-equity ratio of 1.28. The stock’s 50 day simple moving average is $46.98 and its 200-day simple moving average is $36.68. The firm has a market cap of $8.40 billion, a P/E ratio of 19.19, a PEG ratio of 1.33 and a beta of 1.60.

Hedge Funds Weigh In On TG Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Congress Asset Management Co. purchased a new position in TG Therapeutics during the fourth quarter worth about $57,307,000. Nordea Investment Management AB acquired a new position in TG Therapeutics during the fourth quarter worth approximately $2,356,000. Penn Capital Management Company LLC boosted its holdings in shares of TG Therapeutics by 17.6% in the 3rd quarter. Penn Capital Management Company LLC now owns 521,260 shares of the biopharmaceutical company’s stock valued at $18,877,000 after purchasing an additional 77,895 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of TG Therapeutics by 56.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 227,934 shares of the biopharmaceutical company’s stock valued at $8,234,000 after buying an additional 81,907 shares during the period. Finally, M&T Bank Corp purchased a new position in shares of TG Therapeutics in the 4th quarter worth $3,750,000. 58.58% of the stock is owned by institutional investors and hedge funds.

Key TG Therapeutics News

Here are the key news stories impacting TG Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and lifted its price target on TG Therapeutics to $77, which is helping support the stock. TG Therapeutics (TGTX) Gets a Buy from H.C. Wainwright
• Positive Sentiment: Analysts also raised longer-term earnings forecasts for FY2028, FY2029, and FY2030, suggesting confidence in TG Therapeutics’ growth outlook.
• Neutral Sentiment: HC Wainwright lowered near-term estimates for Q2, Q3, Q4 2026 and FY2026, indicating some pressure on expected results in the next few quarters.
• Negative Sentiment: The cut to 2026 earnings expectations could limit enthusiasm if investors focus on short-term execution rather than the longer-term upside case.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.